Analysis of Biomarkers in Patients With Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation Treated With Menin Inhibition.

Sponsor
University of Freiburg
Study ID
NCT07627568
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Study Details

The white blood cells of patients with acute myeloid leukemia that have undergone allogeneic stem cell transplantation will be investigated. These are patient where the leukemia has returned after the transplantation.

Key Dates

First listed
Jun 4, 2026
Start date
May 30, 2026
Status verified
May 2026
Primary completion
May 30, 2027
Completion
May 30, 2027

Study Design

Enrollment
20 participants (estimated)

Arms

  • Arm: AML with NPM1 mutations or KMT2A rearrangements
    AML with NPM1 mutations or KMT2A rearrangements that will be treated with immunotherapy (DLI) and immunmodulatory drugs recommended by the guidelines.

Primary Outcome Measure

Correlative biomarker [ Time Frame: 1 year ]

Central Contacts

Find similar trials

Nationwide
Leukemia (other) trialsOncology trialsBlood cancer trials

Related Studies